MONTREAL, September 13, 2011 – Thrasos Innovation, Inc. today announced that it has initiated a Phase 1 clinical trial to study the safety and tolerability of THR-184, which the Company is developing for the treatment of Acute Kidney Injury (AKI) post-surgery. The Phase 1 study is being conducted by Algorithme Pharma of Laval, Quebec, Canada.
Laval, Friday, April 8, 2011 – Chris Perkin, President and Chief Executive Officer, is pleased to announce the appointments of Ingrid Holmes as Senior Director - Clinical Operations , Matthew Logan as Associate Director - Clinical Operations and Pasquale (Patrick) Omobono as Senior Manager - Clinical Operations.
LAVAL, QC, March 21, 2011 - Algorithme Pharma Inc. (the "Company"), a Canadian clinical contract research organization, with facilities in Laval Québec, Montréal Québec, and through its sister company Simbec Research Limited in Merthyr Tydfil UK, today announced having secured the support of Investissement Québec in the form of a loan, which combined with new equity injection from shareholders of the Company and new credit facility arrangements with the actual principal lenders will allow the company to execute on its strategic plan aiming at growing and diversifying the business.
Algorithme Pharma announces another key strategic appointment.
Laval, Monday, March 7, 2011 – Chris Perkin, President and Chief Executive Officer, is pleased to announce the appointment of Dr. Robert Massé as Vice President – Large Molecule Bioanalysis.